Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Medicinal Chemistry

• Publication date

  1998-07-11

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM980048BPMID 9685230
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence.

  2004cited by this paper
• Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.

  1997cited by this paper
• Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity.

  1997cited by this paper
• Molecular basis of agonism and antagonism in the oestrogen receptor

  1997cited by this paper
• Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats

  1996cited by this paper
• Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.

  1995cited by this paper
• Tissue-selective actions of estrogen analogs.

  1995cited by this paper
• Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

  1994cited by this paper
• Inhibition of growth‐factor‐activated proliferation by anti‐estrogens and effects on early gene expression of mcf‐7 cells

  1993cited by this paper
• Metabolism and enantioselective pharmacokinetics of Casodex in man.

  1993cited by this paper
• Molecular structures, conformational analysis, and preferential modes of binding of 3-aroyl-2-arylbenzo[b]thiophene estrogen receptor ligands: LY117018 and aryl azide photoaffinity labeling analogs.

  1993cited by this paper
• Stereoselective glucuronidation of (R)- and (S)-naproxen by recombinant rat phenol UDP-glucuronosyltransferase (UGT1A1) and its human orthologue.

  1993cited by this paper
• The prevention and treatment of osteoporosis.

  1992cited by this paper
• Nasal absorption of 17 alpha-ethinyloestradiol in the rat.

  1989cited by this paper
• Stereoselective formation of fenoterol-para-glucuronide and fenoterol-meta-glucuronide in rat hepatocytes and enterocytes.

  1986cited by this paper
• 1,2-Diaryl-3,4-dihydronaphthalenes: photofluorogenic ligands for the estrogen receptor.

  1985cited by this paper
• Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys.

  1984cited by this paper
• Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells.

  1984cited by this paper
• Age-related changes in the concentrations of cytosol receptors for sex steroid hormones in the hypothalamus and pituitary gland of the rat.

  1981cited by this paper
• Drug Metabolism by the Gastrointestinal Mucosa

  1981cited by this paper
• Functional heterogeneity of UDP-glucuronyltransferase in rat tissues.

  1980cited by this paper
• Sex-related differences in the regulation of cytoplasmic estrogen receptor levels in responsive tissues of the rat.

  1976cited by this paper
• Mammalian antifertility agents. VI. A novel sequence for the preparation of 1,2-disubstituted 3,4-dihydronaphthalenes.

  1969cited by this paper
• Substituted aminoalkoxytriarylhaloethylenes.

  1967cited by this paper
• Mammalian antifertility agents. IV. Basic 3,4-dihydronaphthalenes and 1,2,3,4-tetrahydro-1-naphthols.

  1967cited by this paper

• ABT, Elacridar and Bile‐Duct Cannulated Rats: Tools to Understand Pharmacokinetics

  2025cites this paper
• A practical synthesis of YZD-7082B, a novel orally bioavailable selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer

  2025cites this paper
• Structural evolution progress of orally bioavailable selective estrogen receptor degraders.

  2025cites this paper
• 1,6-Conjugate hydrogenation of para-quinone methides to phenol-containing diaryl- and triarylmethanes under atmospheric pressure catalyzed by a metal–ligand bifunctional iridium catalyst

  2024cites this paper
• Discovery of Thiochroman Derivatives as Potent, Oral Selective Estrogen Receptor Degraders and Antagonists for the Treatment of Endocrine-Resistant Breast Cancer.

  2024cites this paper
• SERDs: a case study in targeted protein degradation.

  2022cites this paper
• Structure‒tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety

  2022cites this paper
• Discovery of Thieno[2,3-e]indazole Derivatives as Novel Oral Selective Estrogen Receptor Degraders with Highly Improved Antitumor Effect and Favorable Druggability.

  2022cites this paper
• Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer.

  2021cites this paper
• Overcoming Endocrine Resistance in Breast Cancer.

  2020cites this paper
• The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs)

  2020cites this paper
• The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor

  2020cites this paper
• Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927.

  2019cites this paper
• Crystal structure of GDC-0927 bound to estrogen receptor alpha

  2019cites this paper
• Rational approaches of drug design for the development of selective estrogen receptor modulators (SERMs), implicated in breast cancer.

  2019cites this paper
• The First Targeted Therapy to Treat Cancer: The Tamoxifen Tale

  2018cites this paper
• Development of concise two-step catalytic approach towards lasofoxifene precursor nafoxidine.

  2018cites this paper
• A Novel Strategy to Improve Women’s Health: Selective Estrogen Receptor Modulators

  2018cites this paper
• Acid promoted Ir–P^N complex catalyzed hydrogenation of heavily hindered 3,4-diphenyl-1,2-dihydronaphthalenes: asymmetric synthesis of lasofoxifene tartrate

  2017cites this paper
• Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.

  2017cites this paper
• Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.

  2017cites this paper
• Formation of Alkanes and Arenes by Reduction

  2017cites this paper
• Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat.

  2016cites this paper
• Selective estrogen receptor modulators in clinical practice: a safety overview

  2015cites this paper
• Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.

  2015cites this paper
• Cancer chemoprevention at the crossroads

  2015cites this paper
• Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

  2015cites this paper
• Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes

  2014cites this paper
• Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy

  2014cites this paper
• Selective estrogen receptor modulators: tissue specificity and clinical utility

  2014cites this paper
• Selective estrogen receptor modulators: tissue specificity and clinical utility

  2014cites this paper
• An overview of current and emerging SERMs.

  2014cites this paper
• Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.

  2013cites this paper
• Metabolites of Tamoxifen as the Basis of Drug Development

  2013cites this paper
• Nuclear Receptors and Their Selective Pharmacologic Modulators

  2013cites this paper
• Enantiomeric pairs reveal that key medicinal chemistry parameters vary more than simple physical property based models can explain

  2012cites this paper
• Emerging Selective Estrogen Receptor Modulators

  2012cites this paper
• EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis.

  2012cites this paper
• Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis

  2011influential citation
• Evolution of Selective Estrogen and Androgen Receptor Modulators: Status of Current Therapy and New Drug Development

  2011cites this paper
• Induced fit simulations on nuclear receptors.

  2011cites this paper
• An ortho-Quinodimethane Route to Lasofoxifene and U23469

  2011cites this paper
• Lasofoxifene: Selective Estrogen Receptor Modulator for the Prevention and Treatment of Postmenopausal Osteoporosis

  2011cites this paper
• Lasofoxifene in osteoporosis and its place in therapy

  2010cites this paper
• Synthesis of Lasofoxifene, Nafoxidine and Their Positional Isomers via the Novel Three-Component Coupling Reaction

  2010cites this paper
• Chemoprevention of Breast Cancer

  2010cites this paper
• Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene

  2010cites this paper
• Lasofoxifene: Evidence of its therapeutic value in osteoporosis

  2009cites this paper
• Lasofoxifene: a new-generation SERM for the treatment of postmenopausal osteoporosis

  2009cites this paper
• Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy

  2009influential citation
• Identification of xenoestrogens in food additives by an integrated in silico and in vitro approach.

  2009cites this paper
• Synthesis and biological evaluation of 3,4,6-triaryl-2-pyranones as a potential new class of anti-breast cancer agents.

  2009cites this paper
• Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis

  2009cites this paper
• Pharmacology and clinical applications of selective estrogen receptor modulators

  2009cites this paper
• Subtype‐Selective Estrogens

  2008cites this paper
• Pharmacophore mapping of arylbenzothiophene derivatives for MCF cell inhibition using classical and 3D space modeling approaches.

  2008cites this paper
• “DMD #21808” 1 METABOLISM, DISTRIBUTION AND EXCRETION OF A NEXT GENERATION SELECTIVE ESTROGEN RECEPTOR MODULATOR, LASOFOXIFENE, IN RATS AND MONKEYS

  2008cites this paper
• Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio.

  2008cites this paper
• Metabolism, Distribution, and Excretion of a Next Generation Selective Estrogen Receptor Modulator, Lasofoxifene, in Rats and Monkeys

  2008cites this paper
• Prediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical method

  2008cites this paper
• Nuclear Receptors as Drug Targets

  2008cites this paper
• Disposition of Lasofoxifene, a Next-Generation Selective Estrogen Receptor Modulator, in Healthy Male Subjects

  2008influential citation
• New agents in development for breast cancer

  2007cites this paper
• New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

  2007cites this paper
• Chemoprevention of breast cancer with selective oestrogen-receptor modulators

  2007cites this paper
• Synthesis and evaluation of isomeric (17alpha,20E)-11beta-methoxy-21-(trifluoromethylphenyl)-19-norpregna-1,3,5(10),20-tetraene-3,17beta-diols as ERalpha-hormone binding domain ligands: effect of the methoxy group on receptor binding and uterotrophic growth.

  2007cites this paper
• Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis

  2007cites this paper
• Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs).

  2007cites this paper
• SERMs for the treatment and prevention of breast cancer

  2007cites this paper
• Endocrine Modulating Agents

  2007cites this paper
• Synthesis and Evaluation of Isomeric (17α,20E)-11β-Methoxy-21-(trifluoromethylphenyl)-19-norpregna-1,3,5(10),20-tetraene-3,17β-diols as ERα-Hormone Binding Domain Ligands: Effect of the Methoxy Group on Receptor Binding and Uterotrophic Growth

  2007cites this paper
• The 2.0 Å crystal structure of the ERα ligand‐binding domain complexed with lasofoxifene

  2007influential citation
• An expeditious synthesis of lasofoxifene and nafoxidine via the novel three-component coupling reaction

  2007cites this paper
• Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.

  2006cites this paper
• Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis.

  2006cites this paper
• Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.

  2006cites this paper
• Estrogen receptors as therapeutic targets in breast cancer.

  2006cites this paper
• Clinical Pharmacology of Multiple Doses of Lasofoxifene in Postmenopausal Women

  2006cites this paper
• Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward

  2006cites this paper
• Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor &bgr; and androgen receptor in rats

  2006cites this paper
• Effects of Steady-State Lasofoxifene on Cyp2D6- and Cyp2E1-Mediated Metabolism

  2006cites this paper
• Clinical Pharmacology of Lasofoxifene in Japanese and White Postmenopausal Women

  2006cites this paper
• Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis

  2006influential citation
• A Single‐Dose Pharmacokinetic Study of Lasofoxifene in Healthy Volunteers and Subjects With Mild and Moderate Hepatic Impairment

  2006cites this paper
• Effect of Lasofoxifene on the Pharmacokinetics of Digoxin in Healthy Postmenopausal Women

  2005cites this paper
• QSAR studies with E-state index: predicting pharmacophore signals for estrogen receptor binding affinity of triphenylacrylonitriles.

  2005cites this paper
• Estrogen receptor ligands. Part 10: Chromanes: old scaffolds for new SERAMs.

  2005cites this paper
• Differential Effects of Estrogen and Raloxifene on Messenger RNA and Matrix Metalloproteinase 2 Activity in the Rat Uterus

  2005cites this paper
• Recent advances in estrogen receptor modulators.

  2005cites this paper
• Synthesis and evaluation of (17alpha,20Z)-21-(4-substituted-phenyl)-19-norpregna-1,3,5(10),20-tetraene-3,17beta-diols as ligands for the estrogen receptor-alpha hormone binding domain: comparison with 20E-isomers.

  2005cites this paper
• Lasofoxifene

  2005cites this paper
• Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.

  2005cites this paper
• Estrogen receptor ligands. Part 11: Synthesis and activity of isochromans and isothiochromans.

  2005cites this paper
• Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators.

  2004cites this paper
• A new series of estrogen receptor modulators: effect of alkyl substituents on receptor-binding affinity.

  2004cites this paper
• Antiestrogens – Tamoxifen, SERMs and Beyond

  2004cites this paper
• Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists.

  2004cites this paper
• Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in male rats.

  2004cites this paper
• Pre- and postnatal development studies of lasofoxifene, a selective estrogen receptor modulator (SERM), in Sprague-Dawley rats.

  2004cites this paper
• Embryo/fetal toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in rats and rabbits.

  2004cites this paper